Associated Papers
Case Report: Benefits of a NSCLC Patient With EGFR A289G/F287_G288insHA cis Mutations From Immunotherapy in Combination With Antiangiogenesis and Chemotherapy and Sequential Treatment of EGFR-TKI.
Zhang H et al.
Frontiers in Oncology, 2022
Select a paper to view details